Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Rhea-AI Summary
Hansa Biopharma (Nasdaq Stockholm: HNSA) has appointed Maria Törnsén as Chief Operating Officer (COO) and President U.S., effective May 19, 2025. Törnsén brings over 20 years of experience in global and US operations, most recently serving as President North America at Calliditas Therapeutics until its acquisition by Asahi Kasei Corporation in 2024. Her extensive background includes senior leadership roles at Sarepta Therapeutics, Sanofi Genzyme, and Shire plc, where she successfully launched multiple products and led a $1.6Bn global franchise. Törnsén will report to CEO Renée Aguiar-Lucander and join the Executive Committee, bringing her expertise in rare diseases and gene therapy to support IDEFIRIX growth and prepare for upcoming catalysts in H2 2025.
Positive
- Appointment of experienced executive with over 20 years in global and US operations
- Strong track record in rare diseases and gene therapy sectors
- Proven success in launching products and managing $1.6Bn global franchise
- Strategic timing ahead of multiple anticipated catalysts in H2 2025
Negative
- None.
Maria Törnsén has more than 20 years experience across global and US operations, where she held multiple senior commercial leadership roles. Most recently, she held the position of President North America at Calliditas Therapeutics, where she was responsible for the US commercial and medical affairs organization, until it was acquired by Asahi Kasei Corporation of
"We are pleased to welcome Ms Törnsén to the executive management team as COO and President of the US business. She brings invaluable experience in the area of rare diseases and gene therapy, from building commercial organizations, launching new products and driving growth and profitability, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander.
"I am delighted to join Hansa at this exciting time in the company's history. I look forward to working with the Hansa team and leveraging my experience from prior roles, to support the continued growth of IDEFIRIX and prepare for multiple anticipated catalysts in the second half of 2025," said Maria Törnsén.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB,
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
250513-HNSA COO US president_ENG |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-appoints-maria-tornsen-as-chief-operating-officer-and-president-us-302453449.html
SOURCE Hansa Biopharma AB
FAQ
Who is Maria Törnsén and what is her new role at Hansa Biopharma (HNSA)?
What is Maria Törnsén's professional background before joining Hansa Biopharma (HNSA)?
What are the immediate priorities for Maria Törnsén at Hansa Biopharma (HNSA)?
When does Maria Törnsén start her role as COO at Hansa Biopharma (HNSA)?
